Patents by Inventor Sergei Gryaznov

Sergei Gryaznov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220048941
    Abstract: A method of making a compound represented by Formula (I): includes a reducing step, a protecting step, and a phosphitylating step, where X is NH; Y is OCF3, —O(CR42)aCR43, —O(CR42)bOCR43, or —O(CR42)b—CR4?CR42; Z is H; B is adenine (A), guanine (G), thymine (T), cytosine (C), uracil (U), 5-methylcytosine (5-me-C), or a protected version of A, G, T, C, U, or 5-me-C; each R1 is independently C1-6 alkyl or cycloalkyl; R2 is CH2CH2CN or C1-6 alkyl; or R1 and R2 together form an optionally substituted C1-6 cycloalkyl; R3 is H or PG; PG is a protecting group; R4 is independently in each instance H or F; a is 1 or 2; and b is 1, 2, or 3.
    Type: Application
    Filed: October 29, 2021
    Publication date: February 17, 2022
    Applicant: Janssen BioPharma, Inc.
    Inventors: Sergei Gryaznov, Jin Hong, Vivek Kumar Rajwanshi, Leonid Beigelman
  • Patent number: 11180524
    Abstract: The present disclosure relates to compounds and compositions containing 5?-phosphoramidite nucleoside monomers of formulae (I) and (II), and methods of making and use, wherein the substituents are as defined in the appended claims.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: November 23, 2021
    Assignee: Janssen BioPharma, Inc.
    Inventors: Sergei Gryaznov, Jin Hong, Vivek Kumar Rajwanshi, Leonid Beigelman
  • Patent number: 11123294
    Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: September 21, 2021
    Assignee: Exicure Operating Company
    Inventors: Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
  • Publication number: 20210196831
    Abstract: Oligodeoxynucleotide-based immunostimulatory Toll-Like Receptor 9 (TLR9) agonists are described. Also described are compositions comprising the TLR9 agonists, methods of making the TLR9 agonists, and methods of using the TLR9 agonists to treat immune diseases, disorders or conditions, such as viral infections or cancer.
    Type: Application
    Filed: January 5, 2021
    Publication date: July 1, 2021
    Inventors: Sergei GRYAZNOV, Leonid BEIGELMAN, Theodore YUN
  • Publication number: 20210102211
    Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof.
    Type: Application
    Filed: October 8, 2020
    Publication date: April 8, 2021
    Applicant: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Subbarao Nallagatla, Warefta Hasan, Aaron Love, Sergei Gryaznov
  • Publication number: 20210095284
    Abstract: Oligonucleotides comprising modifications at the 2 and/or 3? positions(s) along with methods of making and use against Alzheimer disease and other tauopathies are disclosed.
    Type: Application
    Filed: March 13, 2019
    Publication date: April 1, 2021
    Inventors: Andreas EBNETH, Constantin VAN OUTRYVE D'YDEWALLE, Sergei GRYAZNOV, Saúl MARTINEZ MONTERO, Leonid BEIGELMAN, Vivek Kumar RAJWANSHI
  • Publication number: 20210052497
    Abstract: Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.
    Type: Application
    Filed: September 3, 2020
    Publication date: February 25, 2021
    Inventors: Chad A. Mirkin, Sonbinh T. Nguyen, Resham Singh Banga, Natalia Chernyak, Sergei Gryaznov, Aleksandar Radovic-Moreno, Christopher Mader
  • Publication number: 20210040483
    Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? position(s) along with methods of making and use, e.g., against HBV are disclosed.
    Type: Application
    Filed: October 5, 2020
    Publication date: February 11, 2021
    Applicant: Janssen Biopharma, Inc.
    Inventors: Sergei GRYAZNOV, Leonid BEIGELMAN, Antitsa Dimitrova STOYCHEVA, Saul MARTINEZ MONTERO, Jin HONG, Rajendra K. PANDEY, Vivek Kumar RAJWANSHI, Lakshmipathi PANDARINATHAN, Yi JIN, Bharat BARAL
  • Patent number: 10905767
    Abstract: Oligodeoxynucleotide-based immunostimulatory Toll-Like Receptor 9 (TLR9) agonists are described. Also described are compositions comprising the TLR9 agonists, methods of making the TLR9 agonists, and methods of using the TLR9 agonists to treat immune diseases, disorders or conditions, such as viral infections or cancer.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: February 2, 2021
    Assignee: Janssen BioPharma, Inc.
    Inventors: Sergei Gryaznov, Leonid Beigelman, Theodore Yun
  • Patent number: 10894963
    Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: January 19, 2021
    Assignee: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Subbarao Nallagatla, Warefta Hasan, Aaron Love, Sergei Gryaznov
  • Patent number: 10837018
    Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof. The compositions of the invention are useful for activating agonists of nucleic acid interacting complexes, such as TLRs, stimulating an immune response, and treating diseases such as infectious disease, cancer, allergies, allergic diseases, and autoimmune disease.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: November 17, 2020
    Assignee: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Subbarao Nallagatla, Warefta Hasan, Aaron Love, Sergei Gryaznov
  • Publication number: 20200339996
    Abstract: TNF? antisense oligonucleotides are provided herein. Methods of treating TNF? diseases or disorders using the TNF? antisense oligonucleotides and related products are provided.
    Type: Application
    Filed: July 16, 2020
    Publication date: October 29, 2020
    Applicant: Exicure, Inc.
    Inventors: Christopher C. Mader, Tiffany L. Halo, Sergei Gryaznov, Richard Kang, Weston Daniel
  • Patent number: 10793859
    Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? positions(s) along with methods of making and use, e.g., against HBV are disclosed.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: October 6, 2020
    Assignee: Janssen BioPharma, Inc.
    Inventors: Sergei Gryaznov, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Saul Martinez Montero, Jin Hong, Rajendra K. Pandey, Vivek Kumar Rajwanshi, Lakshmipathi Pandarinathan, Yi Jin, Bharat Baral
  • Patent number: 10792251
    Abstract: Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: October 6, 2020
    Assignees: NORTHWESTERN UNIVERSITY, EXICURE, INC.
    Inventors: Chad A. Mirkin, Sonbinh T. Nguyen, Resham Singh Banga, Natalia Chernyak, Sergei Gryaznov, Aleksandar Radovic-Moreno, Christopher Mader
  • Patent number: 10760080
    Abstract: TNF? antisense oligonucleotides are provided herein. Methods of treating TNF? diseases or Initial Screen of Phosphodiester disorders using the TNF? antisense oligonucleotides and related products are provided.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: September 1, 2020
    Assignee: Exicure, Inc.
    Inventors: Christopher C. Mader, Tiffany L. Halo, Sergei Gryaznov, Richard Kang, Weston Daniel
  • Publication number: 20200270611
    Abstract: Modified oligonucleotides comprising a GalNAc moiety of the present disclosure along with methods of making and use, e.g., against HBV are disclosed.
    Type: Application
    Filed: September 14, 2018
    Publication date: August 27, 2020
    Inventors: Sergei GRYAZNOV, Jin HONG, Rajendra K. PANDEY, Vivek Kumar RAJWANSHI
  • Publication number: 20200255468
    Abstract: The present disclosure relates to compounds and compositions containing 5?-phosphoramidite nucleoside monomers of formulae (I) and (II), and methods of making and use, wherein the substituents are as defined in the appended claims.
    Type: Application
    Filed: September 14, 2018
    Publication date: August 13, 2020
    Inventors: Sergei GRYAZNOV, Jin HONG, Vivek Kumar RAJWANSHI
  • Patent number: 10655127
    Abstract: The present disclosure relates to RNA amidates and thioamidates useful for RNA interference applications. The RNA amidates and thioamidates contain at least one internucleoside linkage chosen from ribo-N3??P5? phosphoramidate (NP) and ribo-N3??P5? thiophosphoramidate (NPS) linkages, and optionally further containing at least one covalently conjugated lipid moiety. Compositions comprising the amidates and thioamidates are disclosed, as are methods for their use in modulating gene expression.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: May 19, 2020
    Assignee: Geron Corporation
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Publication number: 20200069587
    Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
    Type: Application
    Filed: September 12, 2019
    Publication date: March 5, 2020
    Applicant: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
  • Publication number: 20200022913
    Abstract: Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.
    Type: Application
    Filed: January 8, 2019
    Publication date: January 23, 2020
    Inventors: Chad A. Mirkin, Sonbinh T. Nguyen, Resham Singh Banga, Natalia Chernyak, Sergei Gryaznov, Aleksandar Radovic-Moreno, Christopher Mader